Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting CCL7 for diabetic vascular disease

October 7, 2024 5:35 PM UTC

Inhibiting the chemokine CCL7 could help treat diabetic vascular disease by promoting AKT signaling and preventing ERK signaling in endothelial cells, which increases angiogenesis while decreasing inflammation.

CCL7 levels were higher in the plasma and endothelial progenitor cells of blood from Type II diabetic patients than from healthy individuals. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article